Japan Breast Cancer Research Group

This Phase 3 trial tested whether replacing standard taxane chemotherapy (paclitaxel or docetaxel) with eribulin, when combined with pertuzumab and trastuzumab, could control advanced HER2-positive breast cancer just as well while causing less nerve damage. The study enrolled 446…

This phase 3 trial tested whether giving pertuzumab again, along with trastuzumab and chemotherapy, could help people with HER2-positive advanced breast cancer who had already received pertuzumab before. The study enrolled 226 participants and compared retreatment to standard tra…